These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17306191)

  • 1. [Marginal structural models application to estimate the effects of antiretroviral therapy in 5 cohorts of HIV seroconverters].
    Pérez-Hoyos S; Ferreros I; Hernán MA;
    Gac Sanit; 2007; 21(1):76-83. PubMed ID: 17306191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.
    Cole SR; Hernán MA; Robins JM; Anastos K; Chmiel J; Detels R; Ervin C; Feldman J; Greenblatt R; Kingsley L; Lai S; Young M; Cohen M; Muñoz A
    Am J Epidemiol; 2003 Oct; 158(7):687-94. PubMed ID: 14507605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.
    Pérez-Hoyos S; del Amo J; Muga R; del Romero J; García de Olalla P; Guerrero R; Hernàndez-Aguado I;
    AIDS; 2003 Feb; 17(3):353-9. PubMed ID: 12556689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
    Writing Committee for the CASCADE Collaboration
    Arch Intern Med; 2011 Sep; 171(17):1560-9. PubMed ID: 21949165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
    Porter K; Babiker A; Bhaskaran K; Darbyshire J; Pezzotti P; Porter K; Walker AS;
    Lancet; 2003 Oct; 362(9392):1267-74. PubMed ID: 14575971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l.
    Opravil M; Ledergerber B; Furrer H; Hirschel B; Imhof A; Gallant S; Wagels T; Bernasconi E; Meienberg F; Rickenbach M; Weber R;
    AIDS; 2002 Jul; 16(10):1371-81. PubMed ID: 12131214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.
    Hernán MA; Brumback B; Robins JM
    Epidemiology; 2000 Sep; 11(5):561-70. PubMed ID: 10955409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death.
    Westreich D; Cole SR; Young JG; Palella F; Tien PC; Kingsley L; Gange SJ; Hernán MA
    Stat Med; 2012 Aug; 31(18):2000-9. PubMed ID: 22495733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count.
    Cole SR; Hernán MA; Margolick JB; Cohen MH; Robins JM
    Am J Epidemiol; 2005 Sep; 162(5):471-8. PubMed ID: 16076835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy.
    Barrón Y; Cole SR; Greenblatt RM; Cohen MH; Anastos K; DeHovitz JA; Delapenha R; Gange SJ
    AIDS; 2004 Jul; 18(11):1579-84. PubMed ID: 15238776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C and progression of HIV disease.
    Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
    JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.
    Cain LE; Cole SR; Chmiel JS; Margolick JB; Rinaldo CR; Detels R
    Am J Epidemiol; 2006 Feb; 163(4):310-5. PubMed ID: 16371516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
    PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.